Longeveron is focusing on using its primary treatment, laromestrocel, to fight a rare pediatric heart birth defect that devastates families and continues to receive good FDA news regarding its treatment for Alzheimer's Disease, while also expanding its pipeline. The company announced that it has appointed a new CEO with over 30 years of industry experience, while also announcing new cost containment measures. We believe both moves bode well for the future.
